Undeniably, the use of MATT-LTSLs alone is not efficient in killing cancer cells due to MATT’s low toxicity to cells; consequently, the combined use of a cytotoxic agent such as paclitaxel with MATT is a promising treatment approach for metastatic cancer. Here, TMEM79 is linked to metastatic malignant neoplasm.